ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review

(2012) Zhen Wang et al.   BMC GASTROENTEROLOGY

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

(2012) Yung-Jue Bang et al.   LANCET

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

(2011) P. A. Zucali et al.   CLINICAL CANCER RESEARCH

Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

(2011) Mitsuru Sasako et al.   JOURNAL OF CLINICAL ONCOLOGY

Multimodality treatment for localized gastro-oesophageal cancer

(2010) A. F. C. Okines et al.   ANNALS OF ONCOLOGY

Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy

(2010) Ki Han Kim et al.   BIOMARKERS

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

(2010) Aristotelis Bamias et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

(2010)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

(2010) Ilfet Songun et al.   LANCET ONCOLOGY

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

(2009) J-S Kim et al.   BRITISH JOURNAL OF CANCER

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

(2008) J Matsubara et al.   BRITISH JOURNAL OF CANCER

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

(2008) J. H. J. M. van Krieken et al.   VIRCHOWS ARCHIV